Theres no proven link to liver or kidney damage in medically supervised doses
FOXO4-DRI may reduce age-related inflammation Senescent cells often release pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP)
Furthermore, IS activates NF-B signaling, increasing pro-inflammatory factors such as cyclooxygenase-2, ROS, TNF-, IL-6, and IL-1, while suppressing antioxidant factors such as heme oxygenase-1 and superoxide dismutase 2, through Nrf2 pathway inhibition, thereby disrupting intestinal homeostasis and promoting systemic inflammation in mice ( Figure 3 ) [116]
No DAC uncertainty: CJC-1295 No DAC / Modified GRF (1-29) is shorter acting, but direct long-term human safety evidence remains limited
Lipid-based nanosystems were shown to enhance transdermal delivery while reducing systemic toxicity, supporting their clinical translation potential